Réf :HematoStat.net ; 2 (7) : V60 Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, Martinez-Calle N, […]

Réf :HematoStat.net ; 2 (7) : V59 Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. Rigolin GM, Del Giudice I, […]

Réf :HematoStat.net ; 2 (7) : V58 Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, […]

Réf :HematoStat.net ; 2 (7) : V57 The CLL12 trial: ibrutinib vs. placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf […]

Réf. :HematoStat.net ; 2 (7) : R53   Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Al-Sawaf O, Zhang C, Lu T, Liao […]

Réf. :HematoStat.net ; 2 (7) : R52   Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized […]

Réf :HematoStat.net ; 2 (4) : V56 EORTC Quality of Life Group. International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic […]

Réf :HematoStat.net ; 2 (4) : V55 Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy. Voso MT, Pandzic T, […]